LG Chem plans to begin clinical development of an artificial intelligence-supported personalized messenger RNA cancer vaccine in 2029, after targeting preclinical testing in 2027. The company presented the timetable at the first LG AI Bio Conference in Seoul, describing it as part of a precision oncology strategy rather than a confirmed product launch schedule.

The program is intended to analyze the genetic features of each patient’s tumor and use AI to predict neoantigens that could trigger an immune response against cancer cells. LG Chem is also developing models to identify biomarkers linked to treatment response and to select patients who may be more likely to benefit in a clinical trial.

The 2029 milestone is a target for starting clinical development, not evidence that a vaccine will be available by that year. The plan remains subject to preclinical validation, clinical results and subsequent regulatory procedures.

The conference, jointly hosted by LG AI Research and US biotechnology investor Flagship Pioneering, also covered AI-generated drug candidates, autonomous laboratories that repeat design, synthesis, testing and learning, and patient selection using whole-genome and spatial biology data. These tools could connect candidate discovery with trial enrollment, but their value will depend on validation in prospective studies.